Stockholm, 2016-04-14 16:00 CEST (GLOBE NEWSWIRE) --
Today at PledPharma’s Annual General Meeting the company's CEO, Jacques Näsström, presents milestones achieved during the past year. The focus of the presentation is on the company's most advanced project PledOx®. Among others, Näsström mentions that active discussions are being held with a number of potential partners in the ongoing process of finding one or more appropriate commercial partners for continued development.
The full presentation from the AGM is available on the company website.
For more information please contact:
Jacques Näsström, CEO, phone: +46 737 130 979
jacques.nasstrom@pledpharma.se
About PledPharma
PledPharma develop new drugs that protect the body against oxidative stress - a potentially disabling and sometimes life-threatening condition that can be caused by chemotherapy and acetaminophen poisoning. The company's most advanced project PledOx® reduces nerve damage associated with chemotherapy. Positive results from phase IIb study PLIANT were presented in the spring of 2015. The drug candidate Aladote® is developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. The project PP-099 aims to limit the damage that occurs to the heart muscle during a heart attack. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For further information, please visit www.pledpharma.se
